If Afreeza takes off and gains market share, then that may pave the way for a competitor like Oralyn. However, many people won't touch Afreeza because it is inhaled, so we'll see how many people switch to it. A lot of physicians are leery of Afreeza because of the unknown of what it may be doing, unseen, to the lungs.